Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum [Yahoo! Finance]
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at
Wall St
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia [Yahoo! Finance]